Business, energy, technology, markets and global industry news from Business News Today

Phase 3 BASIS trial

Pharma & Biotech

EU backs Pfizer’s Hympavzi for hemophilia patients with inhibitors. What changes now?

Hemophilia care is moving beyond factor replacement. Pfizer’s Hympavzi EU expansion tests how far anti-TFPI therapy can scale.

Read More